Search Result

Results for "

Androgen receptor inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (74) 5 alpha Reductase (5) Adrenergic Receptor (1) Akt (1) Aldose Reductase (1) Apoptosis (19) Aryl Hydrocarbon Receptor (2) Autophagy (1) Bacterial (2) Calcium Channel (1) Cannabinoid Receptor (1) CXCR (1) Cytochrome P450 (3) Drug Metabolite (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (5) Fatty Acid Synthase (FASN) (1) Fungal (8) Glucocorticoid Receptor (2) Histone Acetyltransferase (4) HSV (1) Isotope-Labeled Compounds (3) Mineralocorticoid Receptor (1) MNK (1) NF-κB (1) NO Synthase (1) p38 MAPK (1) Parasite (3) PPAR (2) Progesterone Receptor (2) PROTACs (4) Thyroid Hormone Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1)
By Research Areas:	Cancer (79) Cardiovascular Disease (2) Endocrinology (16) Infection (11) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Cholesterol (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Androgen Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158102

ORIC-944	Others	Cancer
ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

HY-164373

SC428	Androgen Receptor Apoptosis	Cancer
SC428 is an androgen receptor (AR) inhibitor that targets the N-terminal domain. SC428 potently decrease the transactivation of (AR)-V7, (AR)v567es, as well as full-length ( AR ) (AR-FL) and its LBD mutants, substantially. SC428 inhibits androgen-stimulated (AR)-FL nuclear translocation, chromatin binding, and (AR) -regulated gene transcription. SC428 inhibits the proliferation of tumor cells in vitro. SC428 inhibits tumor cell growth by inducing apoptosis in mice transplanted with 22RV1 .

HY-158102A

ORIC-944 TFA	Others	Cancer
ORIC-944 TFA is the TFA salt form of ORIC (HY-158102). ORIC-944 TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .

HY-136582

Masofaniten Androgen receptor-IN-2	Androgen Receptor	Cancer
Masofaniten (Androgen receptor-IN-2) is a potent and orally active **androgen receptor** inhibitor. Masofaniten has antitumor activity against prostate cancer .

HY-118409

VPC-3033	Androgen Receptor	Endocrinology Cancer
VPC-3033 is an **androgen receptor** antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC₅₀: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC₅₀=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002) .

HY-131953

Androgen receptor-IN-3	Androgen Receptor	Cancer
Androgen receptor-IN-3 (Compound 22) is an **androgen receptor** inhibitor. Androgen receptor-IN-3 inhibits AR-driven transcriptional activity in LNCaP cells, with an IC₅₀ of 5.04 μM .

HY-153772

Androgen receptor antagonist 8	Androgen Receptor	Cancer
Androgen receptor antagonist 8 (Example 13) is an **androgen receptor** antagonist. Androgen receptor antagonist 8 inhibits prostate specific antigen secretion in LNcap cell (IC₅₀: 88 nM). Androgen receptor antagonist 8 can be used for prostate cancer research .

HY-160221

Androgen receptor degrader-4	Androgen Receptor	Cancer
Androgen receptor degrader-4 (compound 99) is a select **androgen receptor degrader with an IC₅₀** value of 3 nM. Androgen receptor degrader-4 inhibits the proliferation of prostate cancer cells .

HY-151220

Androgen receptor-IN-4	Androgen Receptor	Others
Androgen receptor-IN-4 (Compound 206) is an **androgen receptor** inhibitor, and can be used for research of Kennedy's disease .

HY-153276

Androgen receptor-IN-5	Androgen Receptor	Cancer
Androgen receptor-IN-5 is an **androgen receptor** inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .

HY-139623

A4B17	Androgen Receptor	Cancer
A4B17 is an **androgen receptor** N-terminal inhibitor for researching androgen-responsive prostate cancer.

HY-155478

Androgen receptor-IN-6	Androgen Receptor	Cancer
Androgen receptor-IN-6 (compound 16) is an orally available androgen receptor (Androgen Receptor) potent inhibitor (IC₅₀=0.12 μM in vitro), targeting the disordered N-terminal domain (NTD). Androgen receptor-IN-6 has good Caco2 cell membrane permeability and has an oral activity (F/%) of 16% in male CD-1 mice .

HY-152524

Androgen receptor antagonist 7	Androgen Receptor	Cancer
Androgen receptor antagonist 7 is an effective **androgen receptor (AR) antagonist with an IC₅₀** value of 1.18 µM. Androgen receptor antagonist 7 has biological activity in vitro and inhibits the expression of AR target in a time and dose dependent manner with an GI₅₀ value of 7.9 µM .

HY-121094

Androgen receptor allosteric antagonist 1	Estrogen Receptor/ERR	Cancer
Androgen receptor allosteric antagonist 1(compound D36)is a a llosteric, competitive androgen receptor (AR) antagonist with the K_i of 9 μM. Androgen receptor allosteric antagonist 1 inhibits R1881-mediated transcription and proliferation and can be used for study of prostate cancer .

HY-105122

Zanoterone WIN 49596	Androgen Receptor	Endocrinology Cancer
Zanoterone is an orally active antagonist of the androgen receptor (AR) with a K_i of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth .

HY-15103

AH3960	Androgen Receptor Thyroid Hormone Receptor	Cancer
AH3960 (compound 16c) is an antagonist of **androgen receptor. AH3960 binds wild as well as T877** mutant type androgen receptors. AH3960 selectively inhibits T877 with an IC₅₀ value of 0.82 μM. AH3960 also serves as an agonist of *parathyroid hormone receptor-1 (PTHR1)* .

HY-16079

AZD3514 3 Publications Verification	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer .

HY-143535

HG122	Androgen Receptor	Cancer
HG122 promotes androgen receptor (AR) degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.

HY-117669

VPC-14228	Androgen Receptor	Cancer
VPC-14228 is a potent androgen receptor DNA binding domain (AR-DBD) inhibitor that interferes with the interaction of AR with androgen response elements and effectively blocks AR transcriptional activity. VPC-14228 can be used in prostate cancer research .

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Endocrinology Cancer
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a *cannabinoid receptor* type 1 (CB1)** agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of **androgen receptor**, which is known to regulate fatty acid synthesis ^[2,3].

HY-164371

(+)-JJ-74-138	Androgen Receptor	Cancer
(+)-JJ-74-138, a novel non-competitive androgen receptor (AR) antagonist, is capable of inhibiting Enzalutamide-resistant CRPC .

HY-160020

ET516	Androgen Receptor	Cancer
ET516 is a potent inhibitor of **Androgen Receptor*. ET516 significantly inhibits* the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants .

HY-123308

VPC13163	Androgen Receptor	Cancer
VPC13163 is a potent androgen receptor (AR) BF3 inhibitor with an IC₅₀ of 0.31 µM. VPC13163 has anticancer effects .

HY-111421

ODM-204	Androgen Receptor Cytochrome P450	Cancer
ODM-204 is novel nonsteroidal dual inhibitor of both **androgen receptor and CYP17A1 enzyme, with IC₅₀**s of 80 nM and 22 nM, respectively.

HY-N0790

Lupeol 3 Publications Verification Clerodol; Monogynol B; Fagarasterol	Androgen Receptor Apoptosis	Cancer
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen **receptor (AR)** inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-142923

AR antagonist 2	Androgen Receptor	Cancer
AR antagonist 2 (compound 58) is a potent androgen receptor (AR) inhibitor with an IC₅₀ of 0.95 μM. AR antagonist 2 has the potential for cancer research .

HY-N2345

Procyanidin B3	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor	Inflammation/Immunology Cancer
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen *receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting* the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-124292

Honokiol DCA 1 Publications Verification Honokiol dichloroacetate	Androgen Receptor	Cancer
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .

HY-N6714

Alternariol	Topoisomerase Androgen Receptor Estrogen Receptor/ERR Apoptosis	Infection Cancer
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen *Receptor) effects. Alternariol can induce apoptosis*, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects .

HY-B0845

Prochloraz BTS 40542	Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor	Infection Endocrinology
Prochloraz is an imidazole antifungal. Prochloraz is as an *estrogen receptor* (ER)** and androgen receptor (AR) antagonist and an aromatase inhibitor with IC₅₀ values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the *aryl hydrocarbon receptor* (AhR) having an EC₅₀** of 1 μM .

HY-13613

Dutasteride 3 Publications Verification GG 745; GI 198745	5 alpha Reductase Apoptosis	Cancer
Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT .

HY-103245

Cl-4AS-1	Androgen Receptor	Cancer
Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC₅₀ = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively) .

HY-N0790R

Lupeol (Standard)	Androgen Receptor Apoptosis	Cancer
Lupeol (Standard) is the analytical standard of Lupeol. This product is intended for research and analytical applications. Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic?triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent?androgen receptor (AR)?inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-114246

ONC1-13B	Others	Cancer
ONC1-13B is a potent androgen receptor (AR) antagonist with the activity of effectively inhibiting PSA expression in prostate cancer cells. ONC1-13B can effectively inhibit PSA expression and prostate cancer cell proliferation under DHT stimulation. ONC1-13B exerts its anti-tumor effect by preventing androgen from binding to AR and its nuclear translocation .

HY-N7210

Kahweol acetate	Apoptosis	Cancer
Kahweol acetate, a bioactive compound found in coffee, has been identified for its potent anti-cancer properties, particularly in inhibiting the proliferation and migration of prostate cancer cells. Alongside cafestol, it shows dose-dependent effects in suppressing tumor growth and metastasis in both in vitro and in vivo studies. Mechanistically, kahweol acetate and cafestol induce apoptosis, inhibit epithelial-mesenchymal transition, and reduce androgen receptor activity, especially in androgen receptor-positive cells. They also downregulate chemokine receptors CCR2 and CCR5, crucial for cancer progression, without altering their ligand levels. These findings suggest that kahweol acetate, in combination with cafestol, may serve as promising therapeutic agents against prostate cancer .

HY-163340

GA32	Glucocorticoid Receptor Androgen Receptor	Cancer
GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC₅₀ values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .

HY-156530

CYP11A1-IN-1	Cytochrome P450	Endocrinology
CYP11A1-IN-1 (compound 30) is an inhibitor of CYP11A1, with IC₅₀ value of 201-2000 nM. CYP11A1-IN-1 can be used for research in steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer .

HY-123163

JNJ-1250132 RWJ-66826; RTI-6617-003	Progesterone Receptor Glucocorticoid Receptor Androgen Receptor Estrogen Receptor/ERR	Endocrinology Cancer
JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC₅₀ of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC₅₀=0.50 nM) and the rat androgen receptor (AR) (IC₅₀=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC₅₀ >3000 nM) .

HY-B0846

Dimethomorph	Fungal Androgen Receptor Parasite	Infection
Dimethomorph is a fungicide belongs to the fungicide group of sterol biosynthesis inhibitor. Dimethomorph can inhibit fungal cell wall formation. Dimethomorph also inhibits androgen receptor (AR) activity in MDA-kb2 cells with an IC₂₀ of 0.263 µM .

HY-N7045

Isosilybin B 1 Publications Verification	Androgen Receptor Apoptosis	Cancer
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation .

HY-N2345R

Procyanidin B3 (Standard)	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor	Inflammation/Immunology Cancer
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-B0845R

Prochloraz (Standard)	Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor	Infection Endocrinology
Prochloraz (Standard) is the analytical standard of Prochloraz. This product is intended for research and analytical applications. Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC₅₀ values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC₅₀ of 1 μM .

HY-B0111

Drospirenone Dihydrospirorenone	Progesterone Receptor Androgen Receptor	Endocrinology Cancer
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the progesterone receptor (PR) and **androgen receptor** (AR). Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. .

HY-156111

ARD-1676	PROTACs Androgen Receptor	Cancer
ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models .

HY-141487

CLP-3094 2 Publications Verification	Androgen Receptor	Metabolic Disease Inflammation/Immunology
CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC₅₀=4 μM) . CLP-3094 is a selective, potent GPR142 antagonist .

HY-109619

D4-abiraterone Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite	Androgen Receptor Cytochrome P450	Cancer
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of **androgen receptor**.

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Androgen Receptor	Inflammation/Immunology Cancer
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-118375

Phenylbutyl isoselenocyanate ISC-4	Apoptosis	Cancer
Phenylbutyl isoselenocyanate (ISC-4) is a selective apoptosis inducer that increases reactive oxygen species levels to inhibit androgen receptor (AR) and activate p53 pathway. Phenylbutyl isoselenocyanate induces apoptosis in LNCaP prostate cancer cells and has anti-prostate cancer properties.

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-109070

Ralaniten EPI-002	Androgen Receptor	Cancer
Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC₅₀ of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC) .

Cat. No.	Product Name

HY-L126

Nuclear Receptor Compound Library

710 compounds

Nuclear receptors (NR) are proteins found in cells that sense androgen and thyroid hormones and certain other molecules. They are ligand-activated transcription factors that participate in many aspects of human physiology and pathology, and regulate the expression of various important genes.

Nuclear receptors have become one of the main targets in the development of new drug strategies, providing a unique type of receptors for studying a variety of human diseases, such as breast cancers, skin disorders and diabetes. 13% of U.S. Food and Drug Administration (FDA) approved drugs target nuclear receptors.

MCE supplies a unique collection of 710 nuclear receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on nuclear receptor. MCE Nuclear Receptor Library is a useful tool for drugs research related to cancer, skin disease and diabetes.

Cat. No.	Product Name	Target	Research Area

HY-P2413

Ac-PPPHPHARIK-NH2	Peptides	Others
Ac-PPPHPHARIK-NH2 (compound S1) is a compound that inhibits the interaction between androgen receptor and Src. It can inhibit the binding of androgen or estrogen-induced receptor and Src in cancer cells, as well as the activation of related signaling pathways, and can also inhibit cell cycle progression and tumor growth.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-110028

Leelamine hydrochloride	Structural Classification other families Classification of Application Fields Pinaceae Terpenoids Source classification Diterpenoids Plants Disease Research Fields Pinus massoniana Lamb. Endocrinology	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a *cannabinoid receptor* type 1 (CB1)** agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of **androgen receptor**, which is known to regulate fatty acid synthesis ^[2,3].

HY-N0790

Lupeol 3 Publications Verification Clerodol; Monogynol B; Fagarasterol	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	Androgen Receptor Apoptosis
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen **receptor (AR)** inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-N2345

Procyanidin B3	Structural Classification Classification of Application Fields Source classification Plants Flavonoids other families Functional Molecules Research of Health Products Phenols Polyphenols Biflavones Disease Research Fields Cancer	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen *receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting* the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N6714

Alternariol	Infection Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	Topoisomerase Androgen Receptor Estrogen Receptor/ERR Apoptosis
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen *Receptor) effects. Alternariol can induce apoptosis*, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects .

HY-N7045

Isosilybin B 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Androgen Receptor Apoptosis
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes androgen receptor (AR) degradation .

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Structural Classification Simaroubaceae Ailanthus altissima (Mill.) Swingle Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Androgen Receptor
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-N7043

Isosilybin A 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Flavanonols Flavonoids Glycine soya Phenols Polyphenols Disease Research Fields Cancer	Apoptosis
Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting *Akt-NF-κB-androgen* receptor (AR)** axis .

HY-N0790R

Lupeol (Standard)	Triterpenes Structural Classification other families Terpenoids Source classification Plants	Androgen Receptor Apoptosis
Lupeol (Standard) is the analytical standard of Lupeol. This product is intended for research and analytical applications. Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic?triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent?androgen receptor (AR)?inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-N7210

Kahweol acetate	Structural Classification Natural Products Source classification Rubiaceae Plants Coffea arabica L.	Apoptosis
Kahweol acetate, a bioactive compound found in coffee, has been identified for its potent anti-cancer properties, particularly in inhibiting the proliferation and migration of prostate cancer cells. Alongside cafestol, it shows dose-dependent effects in suppressing tumor growth and metastasis in both in vitro and in vivo studies. Mechanistically, kahweol acetate and cafestol induce apoptosis, inhibit epithelial-mesenchymal transition, and reduce androgen receptor activity, especially in androgen receptor-positive cells. They also downregulate chemokine receptors CCR2 and CCR5, crucial for cancer progression, without altering their ligand levels. These findings suggest that kahweol acetate, in combination with cafestol, may serve as promising therapeutic agents against prostate cancer .

HY-N2345R

Procyanidin B3 (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Biflavones	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N2908

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-N7043R

Isosilybin A (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Apoptosis
Isosilybin A (Standard) is the analytical standard of Isosilybin A. This product is intended for research and analytical applications. Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis .

HY-113289

Brassicasterol	Infection Animals Classification of Application Fields Source classification Disease Research Fields Steroids Cancer	Akt Androgen Receptor Bacterial Drug Metabolite HSV
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

HY-B0561

Spironolactone 3 Publications Verification SC9420	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and **androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy** and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (AngⅡ)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type Ⅱ diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

Cat. No.	Product Name	Chemical Structure

HY-13613S

Dutasteride-13C6
Dutasteride- ¹³C₆ is the ¹³C labeled Dutasteride[1]. Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT[2].

HY-B0846S

Dimethomorph-d8
Dimethomorph-d₈ is the deuterium labeled Dimethomorph[1]. Dimethomorph is a fungicide belongs to the fungicide group of sterol biosynthesis inhibitor. Dimethomorph can inhibit fungal cell wall formation. Dimethomorph also inhibits androgen receptor (AR) activity in MDA-kb2 cells with an IC20 of 0.263 μM[2][3][4].

HY-13613S2

Dutasteride-13C,15N,d
Dutasteride- ¹³C, ¹⁵N,d is ¹⁵N and deuterated labeled Dutasteride (HY-13613). Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT .

HY-116214S1

Cyprodinil-13C6

Cyprodinil- ¹³C₆ is the ¹³C₆ labeled Cyprodinil. Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 µM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC50=1.91 µM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC50=15.1 µM).

HY-116214S

Cyprodinil-d5

Cyprodinil-d₅is the deuterium labeledCyprodinil(HY-116214) . Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 μM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC₅₀=1.91 μM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC₅₀=15.1 μM) .

Cat. No.	Product Name		Classification